Cargando…

Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01

The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority, and will be required to eradicate polio. In addition, such a vaccine constitutes the only realistic polio vaccine in the post-eradication era. One way to reduce the cost of a vaccine is to increase immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietrich, Jes, Andreasen, Lars Vibe, Andersen, Peter, Agger, Else Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067388/
https://www.ncbi.nlm.nih.gov/pubmed/24956110
http://dx.doi.org/10.1371/journal.pone.0100879
_version_ 1782322289337958400
author Dietrich, Jes
Andreasen, Lars Vibe
Andersen, Peter
Agger, Else Marie
author_facet Dietrich, Jes
Andreasen, Lars Vibe
Andersen, Peter
Agger, Else Marie
author_sort Dietrich, Jes
collection PubMed
description The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority, and will be required to eradicate polio. In addition, such a vaccine constitutes the only realistic polio vaccine in the post-eradication era. One way to reduce the cost of a vaccine is to increase immunogenicity by use of adjuvants. The CAF01 adjuvant has previously been shown to be a safe and potent adjuvant with several antigens, and here we show that in mice IPV formulated with CAF01 induced increased systemic protective immunity measured by binding and neutralization antibody titers in serum. CAF01 also influenced the kinetics of both the cellular and humoral response against IPV to produce a faster, as well as a stronger, response, dominated by IgG2a, IgG2b, and IgG2c isotypes as well as IPV specific T cells secreting IFN-γ/IL-2. Finally, as intestinal immunity is also a priority of polio vaccines, we present a vaccine strategy based on simultaneous priming at an intradermal and an intramuscular site that generate intestinal immune responses against polio virus. Taken together, the IPV-CAF01 formulation constitutes a new promising vaccine against polio with the ability to generate strong humoral and cellular immunity against the polio virus.
format Online
Article
Text
id pubmed-4067388
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40673882014-06-25 Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01 Dietrich, Jes Andreasen, Lars Vibe Andersen, Peter Agger, Else Marie PLoS One Research Article The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority, and will be required to eradicate polio. In addition, such a vaccine constitutes the only realistic polio vaccine in the post-eradication era. One way to reduce the cost of a vaccine is to increase immunogenicity by use of adjuvants. The CAF01 adjuvant has previously been shown to be a safe and potent adjuvant with several antigens, and here we show that in mice IPV formulated with CAF01 induced increased systemic protective immunity measured by binding and neutralization antibody titers in serum. CAF01 also influenced the kinetics of both the cellular and humoral response against IPV to produce a faster, as well as a stronger, response, dominated by IgG2a, IgG2b, and IgG2c isotypes as well as IPV specific T cells secreting IFN-γ/IL-2. Finally, as intestinal immunity is also a priority of polio vaccines, we present a vaccine strategy based on simultaneous priming at an intradermal and an intramuscular site that generate intestinal immune responses against polio virus. Taken together, the IPV-CAF01 formulation constitutes a new promising vaccine against polio with the ability to generate strong humoral and cellular immunity against the polio virus. Public Library of Science 2014-06-23 /pmc/articles/PMC4067388/ /pubmed/24956110 http://dx.doi.org/10.1371/journal.pone.0100879 Text en © 2014 Dietrich et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Dietrich, Jes
Andreasen, Lars Vibe
Andersen, Peter
Agger, Else Marie
Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
title Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
title_full Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
title_fullStr Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
title_full_unstemmed Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
title_short Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
title_sort inducing dose sparing with inactivated polio virus formulated in adjuvant caf01
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067388/
https://www.ncbi.nlm.nih.gov/pubmed/24956110
http://dx.doi.org/10.1371/journal.pone.0100879
work_keys_str_mv AT dietrichjes inducingdosesparingwithinactivatedpoliovirusformulatedinadjuvantcaf01
AT andreasenlarsvibe inducingdosesparingwithinactivatedpoliovirusformulatedinadjuvantcaf01
AT andersenpeter inducingdosesparingwithinactivatedpoliovirusformulatedinadjuvantcaf01
AT aggerelsemarie inducingdosesparingwithinactivatedpoliovirusformulatedinadjuvantcaf01